Interra Health

Overview

Interra Health is an access-workflow technology company formed in 2026 from DoseSpot, Arrive Health, and pVerify. The useful buyer read is that Interra sits upstream in the prescribing workflow: it combines ePrescribing infrastructure with real-time prescription benefit transparency, medical benefit verification, eligibility checks, and coverage / cost insights before a prescription reaches the pharmacy counter.

For manufacturer teams, Interra is most relevant when a launch needs better point-of-care visibility into coverage, affordability, alternative therapies, pharmacy choice, or medical-benefit status. It should not be evaluated like a hub services vendor or specialty pharmacy. The diligence question is whether Interra’s provider-workflow footprint and data-sharing model can support the brand’s access strategy directly, or whether it is better treated as an ecosystem partner through EHR, payer, PBM, or provider channels.

Reimbursement and PA Capability Model

The framework below standardizes how Rx Almanac evaluates reimbursement-prior-auth capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Interra Health is evaluated as access-workflow technology company formed in 2026 from DoseSpot, Arrive Health, and pVerify.

Capability	Buyer should compare	Interra Health readout
Electronic PA initiation and payer connectivity	ePA submission, payer integrations, plan-specific requirements, real-time decisioning, and transaction reach.	PA casework. Interra is strongest upstream in prescribing, benefit transparency, and eligibility; confirm any direct ePA initiation or payer-decisioning scope before treating it as a PA execution platform.
Benefits verification and coverage discovery	Eligibility, pharmacy/medical benefit checks, policy criteria, coverage route, and reimbursement path identification.	Core coverage workflow. pVerify adds medical benefit verification and eligibility checks, while Arrive Health brings real-time prescription benefit transparency.
Clinical documentation and appeals support	Document collection, criteria matching, appeal packets, peer-to-peer prep, and denial management.	Confirm PA casework in the RFP. Public materials position Interra around prescribing and access visibility, not downstream appeal packet assembly or hub case management.
Provider workflow integration	EHR, portal, fax, call, pharmacy, and practice-management workflows that reduce office burden.	Core network reach. DoseSpot gives the combined platform embedded ePrescribing infrastructure for provider-facing software environments.
Automation, AI, and queue prioritization	AI agents, rules engines, form completion, status retrieval, queue triage, and exception handling.	Confirm automation workflow in the RFP. Do not assume AI-driven PA automation from public profile language; ask what workflow steps are automated end to end.
Reporting, status visibility, and policy intelligence	Case status, payer trend reporting, denial reasons, turnaround metrics, and policy-change intelligence.	Reporting layer. Interra can expose coverage, cost, formulary, alternative-therapy, pharmacy, and benefit data; manufacturer-facing reporting and policy analytics should be scoped explicitly.

Buyer Fit

• Procurement trigger: Include Interra when the launch access problem starts at the point of prescribing: cost surprise, coverage uncertainty, formulary / alternative-therapy visibility, medical-benefit verification, or pharmacy-choice friction.
• Strongest buyer fit: Provider, EHR, health-tech, payer, PBM, and manufacturer teams that need embedded access intelligence inside prescribing workflows.
• Commercial fit: Expect a platform / integration-led sale rather than a traditional hub operations SOW. Validate implementation timelines, integration endpoints, data rights, and manufacturer-facing reporting.
• Where it is weaker: Interra is not a replacement for a full hub, specialty pharmacy, field reimbursement team, or appeals operations vendor unless those services are separately contracted through partners.
• Program diligence: Confirm the payer and EHR connections live for the relevant prescriber base, specialty product class, benefit route, and launch geography.

Differentiators

• Three-part access stack: DoseSpot contributes ePrescribing, Arrive Health contributes real-time prescription benefit transparency, and pVerify contributes eligibility and medical benefit verification.
• Upstream workflow position: Interra can influence prescribing and affordability decisions before abandonment risk appears at the pharmacy counter.
• Embedded distribution model: The platform is designed for EHR, telehealth, practice-management, and health-tech integration rather than only a standalone portal workflow.
• Pharmacy and cost visibility: Coverage, cost, pharmacy, and alternative-therapy data can help providers and patients make more informed medication decisions.

RFP Questions

• Which EHR, ePrescribing, telehealth, and practice-management integrations are live for the target prescriber universe?
• Which pharmacy-benefit, medical-benefit, formulary, eligibility, and cost fields are available in real time?
• What data can flow back to hub, specialty pharmacy, field reimbursement, payer account, and manufacturer analytics teams?
• How does the platform initiate PA or only surface coverage and benefit intelligence before PA is needed?
• How are pVerify medical-benefit checks connected to pharmacy-benefit and prescription workflows?
• What implementation work is required from the manufacturer versus the provider, payer, PBM, or EHR partner?

Recent Activity

• Interra Health was formed in March 2026 through the combination of DoseSpot and Arrive Health, with pVerify included in the combined access and benefit-verification platform.
• 2026: The public launch positioned the company around medication transparency for patients and providers, with ePrescribing, real-time benefit, and medical benefit verification as the core operating pillars.